Evidence map›Paper›PMID 36826989›Full record

ArticleeLife2023

Gating interactions steer loop conformational changes in the active site of the L1 metallo-β-lactamase.

Zhuoran Zhao, Xiayu Shen, Shuang Chen, Jing Gu, Haun Wang, Maria F Mojica, Moumita Samanta, Debsindhu Bhowmik, Alejandro J Vila, Robert A Bonomo and 1 more

Abstract read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Deciphering the Coevolutionary Dynamics of L2 β-Lactamases via Deep Learning.Journal of chemical information and modeling · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhuoran Zhao *Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University College London, London, United Kingdom.
Xiayu Shen *Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University College London, London, United Kingdom.
Shuang ChenDepartment of Pharmaceutical and Biological Chemistry, School of Pharmacy, University College London, London, United Kingdom.
Jing GuDepartment of Pharmaceutical and Biological Chemistry, School of Pharmacy, University College London, London, United Kingdom.
Haun WangDepartment of Pharmaceutical and Biological Chemistry, School of Pharmacy, University College London, London, United Kingdom.
Maria F MojicaDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, United States.ORCID 0000-0002-1380-9824
Moumita SamantaCollege of Computing, Georgia Institute of Technology, Atlanta, United States.
Debsindhu BhowmikComputer Science and Engineering Division, Oak Ridge National Laboratories, Oak Ridge, United States.ORCID 0000-0001-7770-9091
Alejandro J VilaCWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, United States.ORCID 0000-0002-7978-3233
Robert A BonomoDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, United States.
Shozeb HaiderDepartment of Pharmaceutical and Biological Chemistry, School of Pharmacy, University College London, London, United Kingdom.ORCID 0000-0003-2650-2925

Funding

A Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4M
NCEZID CDC HHS U54 CK000603NIAID NIH HHS R01 AI100560
6 · The paper itself

Abstract

β-Lactam antibiotics are the most important and widely used antibacterial agents across the world. However, the widespread dissemination of β-lactamases among pathogenic bacteria limits the efficacy of β-lactam antibiotics. This has created a major public health crisis. The use of β-lactamase inhibitors has proven useful in restoring the activity of β-lactam antibiotics, yet, effective clinically approved inhibitors against class B metallo-β-lactamases are not available. L1, a class B3 enzyme expressed by

Indexed as

Anti-Bacterial Agentsbeta-LactamasesCatalytic DomainPenicillinsAnti-Bacterial Agentsbeta-lactamase L1beta-LactamasesPenicillinsanti-bacterial resistancedeep learningL1 metallo-β-lactamasemolecular biophysicsmolecular dynamicsphysics of living systemsStenotrophomonas maltophiliastructural biologyβ-lactam antibiotics

Identifiers

PMID36826989
PMCPMC9977270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.